Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2011 |
| End Date: | December 2014 |
Feasibility of Half-Dose Radiopharmaceutical Administration Utilizing Wide-Beam Reconstruction
This study is recruiting patients already scheduled for a single photon emission computed
tomography myocardial perfusion imaging (SPECT-MPI) test. SPECT-MPI is a nuclear imaging
technique that uses a radioactive substance, or radiotracer, and special equipment to create
three-dimensional (3D) images of the heart. Radiotracer is a radioactive dye that will make
the structures of the heart visible and is routinely used to view blood flow in the heart,
scan for damaged heart tissue, or assess heart function.
For a routine SPECT-MPI test, the radiotracer is given in one dose at the beginning of the
test, followed by taking resting images of the heart. For this study, researchers would like
to administer half of the radiotracer, obtain resting images, administer the remainder of
the radiotracer and obtain a second set of resting images. Participants will receive the
same amount of radioactive material that would normally be given for this test; however, it
will be administered in two half-doses. Participation in this study will add about 30
minutes to the time it takes to complete the routine test. The investigators expect to
enroll about 160 subjects in this study at Northwestern.
tomography myocardial perfusion imaging (SPECT-MPI) test. SPECT-MPI is a nuclear imaging
technique that uses a radioactive substance, or radiotracer, and special equipment to create
three-dimensional (3D) images of the heart. Radiotracer is a radioactive dye that will make
the structures of the heart visible and is routinely used to view blood flow in the heart,
scan for damaged heart tissue, or assess heart function.
For a routine SPECT-MPI test, the radiotracer is given in one dose at the beginning of the
test, followed by taking resting images of the heart. For this study, researchers would like
to administer half of the radiotracer, obtain resting images, administer the remainder of
the radiotracer and obtain a second set of resting images. Participants will receive the
same amount of radioactive material that would normally be given for this test; however, it
will be administered in two half-doses. Participation in this study will add about 30
minutes to the time it takes to complete the routine test. The investigators expect to
enroll about 160 subjects in this study at Northwestern.
Subjects in this study will proceed to the nuclear cardiology laboratory for their scheduled
nuclear stress test. After informed consent is obtained, the study doctor or research staff
member will ask detailed questions about the subject's current health, medications and
medical history, and the subject's medical chart will be reviewed including results of any
previous nuclear images.
For the test, a small catheter (tube) will be placed in a vein in the subject's arm to
administer the radioactive imaging agent, Tc-99m sestamibi. Subjects will be given half
(1/2) of the normal Tc-99m sestamibi dose and then the study staff will obtain resting
images pictures of the heart. After this set of images, the subject will be given the
remaining half of the radioactive imaging agent followed by a second set of images.
After this, the subject will then undergo the stress portion of the test in the usual manner
as prescribed by the referring physician.
nuclear stress test. After informed consent is obtained, the study doctor or research staff
member will ask detailed questions about the subject's current health, medications and
medical history, and the subject's medical chart will be reviewed including results of any
previous nuclear images.
For the test, a small catheter (tube) will be placed in a vein in the subject's arm to
administer the radioactive imaging agent, Tc-99m sestamibi. Subjects will be given half
(1/2) of the normal Tc-99m sestamibi dose and then the study staff will obtain resting
images pictures of the heart. After this set of images, the subject will be given the
remaining half of the radioactive imaging agent followed by a second set of images.
After this, the subject will then undergo the stress portion of the test in the usual manner
as prescribed by the referring physician.
Inclusion Criteria:
- Patients over the age of 18 years
- Undergoing nuclear stress testing
- History of myocardial infarction, cardiomyopathy, heart failure or prior nuclear
studies with resting perfusion defects
Exclusion Criteria:
- Unwilling or unable to undergo an additional resting SPECT acquisition
- Clinical contraindications to nuclear stress testing including acute myocardial
infarction
- For patients undergoing exercise treadmill stress testing:
- Left bundle branch block or artificial ventricular pacemaker
- For patients undergoing regadenoson (Lexiscan) stress testing:
- Moderate to severe chronic obstructive pulmonary disease or asthma, second- or third
degree atrioventricular block or sinus node disease (unless patients have a
functioning artificial pacemaker), known hypersensitivity to aminophylline or
adenosine
- Inability to give informed consent
We found this trial at
1
site
Click here to add this to my saved trials
